靴子落地！盟科药业定增获股东大会通过，罢免议案被否

Core Viewpoint - The company has successfully passed all resolutions related to the issuance of shares to specific investors during the 2025 second extraordinary general meeting, despite opposition from its largest shareholder, Genie Pharma [2][5]. Group 1: Share Issuance Resolutions - All resolutions regarding the issuance of shares to specific investors were approved, including the proposal on the conditions for issuing shares and the plan for the issuance [2][5]. - The approval rates for key resolutions exceeded 81%, with the proposal on the conditions for issuing shares receiving a 81.73% approval rate [5]. Group 2: Opposition from Genie Pharma - Genie Pharma, holding 10.92% of the company's shares, opposed all resolutions except for one and did not receive any voting rights delegation from other shareholders [4][5]. - Genie Pharma proposed additional resolutions to dismiss certain board members and to elect new members, including the current chairman [4]. Group 3: Fundraising Details - The company plans to raise up to 1.033 billion yuan (approximately 10.33 million) through the issuance of 164 million shares to Nanjing Haijing Pharmaceutical Co., Ltd., which will acquire a 20% stake in the company [7][8]. - The funds raised will be used for daily research and operational investments, enhancing the company's capabilities in drug development and commercialization [7][8].